A Houston 503A mail-order compounder focused on weight loss, peptides/longevity, and hormones — with an accreditation gap worth knowing.
This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.
ReviveRx is a consumer-facing 503A mail-order compounding pharmacy popular in the peptide/longevity crowd. It’s patient-specific 503A (state-regulated), not a 503B outsourcing facility.
Facility & accreditation
ReviveRx (reviverx.com; Houston, TX) describes itself as a licensed 503A mail-order compounding pharmacy, founded 2016 and compounding since 2018 [1]. It is not on the FDA 503B list [3]. On accreditation, ReviveRx does not appear in ACHC’s PCAB directory and makes no PCAB claim we could find [2] — so, unlike Empower or Hallandale, its compounding isn’t PCAB-accredited as far as the accreditor’s own registry shows. The site references a “successful FDA inspection,” which we could not independently verify. Note the correct domain is reviverx.com (revive-rx.com is an unrelated site).
What they compound
On-audience: weight loss, a peptide & longevity line, men’s and women’s hormone therapy, sexual wellness, thyroid, and fertility [1]. The company says it ships to 45 states plus Puerto Rico [1].
Regulatory record
On September 22, 2025 the FDA sent ReviveRx a warning letter, addressed to Revive Rx LLC at 3831 Golf Drive, Houston, after an inspection from January 27 to February 7, 2025 [4]. It concerns how the pharmacy makes sterile products: vials exposed to air of a lower grade than the aseptic area requires, microbial contamination recovered inside the aseptic area without an adequate evaluation of the products made there, media fills and airflow studies that did not reflect real working conditions, and no meaningful environmental monitoring inside the units where sterile work is done. FDA judged several of the corrective actions in the pharmacy’s response deficient and could not evaluate others. The letter names no telehealth platform.
FDA’s list of actions against compounders also records a later Form 483 for ReviveRx, issued March 27, 2026, and an untitled letter from 2023 [5]. A Form 483 records an investigator’s observations; it is not a final finding of violation.
ReviveRx is not on the FDA 503B list [3]. The letter is in our register of warning letters to compounding pharmacies.
The read
An on-audience 503A with clear peptide/GLP-1/HRT offerings and real consumer following. Two caveats. The 2025 warning letter is about sterile production, which covers its injectables, and a further inspection in 2026 ended in a Form 483. And the accreditation gap: no PCAB found in ACHC’s registry and only a self-stated (unverified) FDA inspection — so it sits a notch below the PCAB-verified operators here on independent quality signals.
References
- ReviveRx — official site. (accessed 2026-07-01)
- ACHC / PCAB accredited-organization directory (searched “Revive”; not found). (accessed 2026-10-27)
- FDA — Registered Outsourcing Facilities (503B) list (ReviveRx not listed → confirms 503A). (accessed 2026-07-01)
- FDA — Warning letter to Revive Rx LLC dba Revive Rx Pharmacy, MARCS-CMS 709509, September 22, 2025. (accessed 2026-10-21)
- FDA — Compounding: Inspections, Recalls, and other Actions (Revive RX LLC entry). (accessed 2026-10-21)